Insilico Medicine has administered the first dose of INS018_055 to patients in a Phase II clinical trial. The potential anti-fibrosis drug is being tested across multiple regions, including the US and China, after completing earlier human safety studies.
From AI design to patient testing
INS018_055 brings together two uses of artificial intelligence in drug development: the company describes both its target and its molecular structure as novel and AI-generated or AI-discovered. It is now at a clinical stage where researchers can study the candidate in patients.
The drug candidate previously completed Phase 0 and Phase I human safety studies. The move into Phase II marks a further step in its evaluation, but the source does not report trial results or establish whether the treatment is safe or effective for patients.
A candidate for pulmonary fibrosis
INS018_055 is being developed as a possible treatment for pulmonary fibrosis. Insilico Medicine says it could offer an additional treatment option for people with the condition, with particular interest in idiopathic pulmonary fibrosis (IPF).
IPF is described as a specific form of pulmonary fibrosis that causes progressive and irreversible loss of lung function. That description helps explain the medical need the company hopes the candidate might address. Whether INS018_055 can help patients remains to be determined through clinical research.
What the trial stage tells us
Reaching Phase II means the candidate has moved beyond early human safety studies and is now being tested in patients. It is a meaningful development milestone for a drug designed with generative AI, while still leaving key questions open.
The source does not provide details about the trial's size, its methods, or when results may be available. It also does not report outcomes from the studies in mice that the company conducted in 2019. The first dose is therefore news about progress into testing, not evidence that the drug works.
Clinical trials are where researchers assess a candidate in people. For INS018_055, the multi-regional Phase II trials in the US and China will add to the evidence gathered in earlier studies. The source gives no findings from the current trials.
Insilico's case for generative AI
Insilico Medicine presents the drug as evidence of its approach to AI-assisted research and development. Alex Zhavoronkov, PhD, Founder and Co-CEO of Insilico Medicine, said the company had chosen generative AI early and could now demonstrate what he called substantial R&D performance boosts and clinical-stage drugs imagined by AI.
That is the company's assessment of its work. The reported milestone is specific: INS018_055, with an AI-discovered target and AI-generated molecular structure, has reached patient testing in Phase II. The trial's results will determine what can be said about its potential as a treatment.